These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9727065)

  • 21. Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection.
    Enomoto M; Nishiguchi S; Tamori A; Kozuka R; Hayashi T; Kohmoto MT; Jomura H; Morikawa H; Murakami Y; Shiomi S; Kawada N
    J Interferon Cytokine Res; 2015 Aug; 35(8):613-20. PubMed ID: 25884105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
    Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
    Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
    Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
    J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.
    Boni C; Penna A; Bertoletti A; Lamonaca V; Rapti I; Missale G; Pilli M; Urbani S; Cavalli A; Cerioni S; Panebianco R; Jenkins J; Ferrari C
    J Hepatol; 2003 Oct; 39(4):595-605. PubMed ID: 12971971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.
    Sun LJ; Yu JW; Zhao YH; Kang P; Li SC
    J Gastroenterol Hepatol; 2010 Mar; 25(3):583-90. PubMed ID: 19968744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    Nebbia G; Garcia-Diaz A; Ayliffe U; Smith C; Dervisevic S; Johnson M; Gilson R; Tedder R; Geretti AM
    J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum HBsAg level and its clinical significance in lamivudine treatment for patients with HBeAg-negative acute-on-chronic liver failure.
    Lai J; Sun HX; Jie YS; Zhang K; Ke WM
    Int J Infect Dis; 2014 May; 22():78-82. PubMed ID: 24518440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
    Demirören K; Kocamaz H; Doğan Y
    Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Early prediction of lamivudine response in e antigen-negative chronic hepatitis B patients].
    Li JG; Li JX; Liu MX; Qin HQ; Chai YY; Wang XY; Li SF; Tian SW; Zhao LF; Niu Q; Zhang JQ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):745-9. PubMed ID: 19874689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
    Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
    Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.
    Huang YW; Takahashi S; Tsuge M; Chen CL; Wang TC; Abe H; Hu JT; Chen DS; Yang SS; Chayama K; Kao JH
    Antivir Ther; 2015; 20(4):369-75. PubMed ID: 24739420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.
    Yao CC; Lee CM; Hung CH; Wang JH; Hu TH; Lu SN; Changchien CS; Hsu MC; Chen CH
    J Gastroenterol Hepatol; 2015 May; 30(5):918-24. PubMed ID: 25532588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
    Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.